News Roche builds in obesity with $5.3bn Zealand licensing deal Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma.
News J&J abandons work with Genmab on Darzalex successor Genmab is facing increased pressure to deliver on its in-house pipeline after Johnson & Johnson exited a partnership on a Darzalex follow-up.
News AbbVie pays Gubra $350m upfront to enter obesity field AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing an amylin agonist from Gubra in a $2.2bn-plus deal.
News Kyorin partners Hyfe to develop DTx for chronic cough Kyorin Pharma has signed a deal with Hyfe to develop a digital therapeutic (DTx) for people with chronic cough and launch it in Japan.
News Lyfegen partners EVERSANA on pricing, access resource Lyfegen and EVERSANA have joined forces to help pharma companies navigate an increasingly complex global drug pricing and access environment.
News GSK backs £50m Oxford University cancer vaccine programme A GSK alliance with Oxford University aims to identify precancerous changes in cells that could form the basis of preventive vaccines.
Market Access Unpacking Trump’s executive order on drug pricing, with Alic... Jonah Comstock welcomed back Alice Valder Curran to the podcast to pick apart Trump's Executive Order order piece by piece.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
